Hutchison China Meditech Limited Director's Share Dealing (8020R)
December 14 2016 - 2:14AM
UK Regulatory
TIDMHCM
RNS Number : 8020R
Hutchison China Meditech Limited
14 December 2016
Director's Share Dealing
London: Wednesday, December 14, 2016: Hutchison China MediTech
Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notification
that Mr Simon To, Executive Director and Chairman, purchased a
total of 52,161 American Depositary Shares of the Company ("ADSs",
each representing one half of one ordinary share of US$1.00 each in
the capital of Chi-Med ("Ordinary Share")) at an average price of
US$14.18 per ADS on December 9, 2016, December 12, 2016 and
December 13, 2016.
Following the above purchase of 52,161 ADSs, Mr To is interested
in 52,161 ADSs and 180,000 Ordinary Shares (including the holding
of 78,000 Ordinary Shares in a family trust of which his family
members are the beneficiaries), representing approximately 0.34% of
the current issued share capital of Chi-Med.
The notification set out below is provided in accordance with
the requirements of the EU Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person closely associated
---- ----------------------------------------------------------------------------------------------------------------
a) Name Mr Simon To
---- ------------------------------------------------------- -------------------------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------------------------------------------------------
a) Position/status Executive Director and Chairman
---- ------------------------------------------------------- -------------------------------------------------------
b) Initial notification/Amendment Initial notification
---- ------------------------------------------------------- -------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
---- ----------------------------------------------------------------------------------------------------------------
a) Name Hutchison China MediTech Limited
---- ------------------------------------------------------- -------------------------------------------------------
b) LEI N/A
---- ------------------------------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
---- ----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of ADS each representing one half of one Ordinary Share
instrument of US$1.00
Identification code ADS ISIN: US44842L1035
---- ------------------------------------------------------- -------------------------------------------------------
b) Nature of the transaction Acquisition of ADSs
---- ------------------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
US$14.05 10,000
---------- ----------
---- ------------------------------------------------------- -------------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
---- ------------------------------------------------------- -------------------------------------------------------
e) Date of the transaction 2016-12-09
---- ------------------------------------------------------- -------------------------------------------------------
f) Place of the transaction Nasdaq Stock Market
---- ------------------------------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
---- ----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of ADS each representing one half of one Ordinary Share
instrument of US$1.00
Identification code ADS ISIN: US44842L1035
---- ------------------------------------------------------- -------------------------------------------------------
b) Nature of the transaction Acquisition of ADSs
---- ------------------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
US$14.12 30,000
---------- ----------
---- ------------------------------------------------------- -------------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
---- ------------------------------------------------------- -------------------------------------------------------
e) Date of the transaction 2016-12-12
---- ------------------------------------------------------- -------------------------------------------------------
f) Place of the transaction Nasdaq Stock Market
---- ------------------------------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
---- ----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of ADS each representing one half of one Ordinary Share
instrument of US$1.00
Identification code ADS ISIN: US44842L1035
---- ------------------------------------------------------- -------------------------------------------------------
b) Nature of the transaction Acquisition of ADSs
---- ------------------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
US$14.43 12,161
---------- ----------
---- ------------------------------------------------------- -------------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
---- ------------------------------------------------------- -------------------------------------------------------
e) Date of the transaction 2016-12-13
---- ------------------------------------------------------- -------------------------------------------------------
f) Place of the transaction Nasdaq Stock Market
---- ------------------------------------------------------- -------------------------------------------------------
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which
researches, develops, manufactures and sells pharmaceuticals and
healthcare products. Its Innovation Platform, Hutchison MediPharma
Limited, focuses on discovering and developing innovative
therapeutics in oncology and autoimmune diseases for the global
market. Its Commercial Platform manufactures, markets, and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 0001). For more information,
please visit: www.chi-med.com.
Contacts
Investor Enquiries
Christian Hogg, CEO +852 2121 8200
International Media Enquiries
Anthony Carlisle, +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk
Citigate Dewe Rogerson
U.S. Based Media Enquiries
Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com
Investor Relations
Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) mbeck@troutgroup.com
David Dible, +44 7967 566 919 (Mobile) david.dible@citigatedr.co.uk
Citigate Dewe Rogerson
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLIFLDFVLSLIR
(END) Dow Jones Newswires
December 14, 2016 02:14 ET (07:14 GMT)